SE509359C2 - Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel - Google Patents

Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel

Info

Publication number: SE509359C2
Authority: SE; Sweden
Prior art keywords: protein; binding; peptide; life; vivo
Prior art date: 1989-08-01

Application number

SE8902638A

Other languages

English (en)

Swedish (sv)

Other versions

SE8902638D0 (sv

SE8902638L (sv

Inventor

Per-Aake Nygren

Hans Wigzell

Mathias Uhlen

Original Assignee

Cemu Bioteknik Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-08-01

Filing date

1989-08-01

Publication date

1999-01-18

1989-08-01 Application filed by Cemu Bioteknik Ab filed Critical Cemu Bioteknik Ab

1989-08-01 Priority to SE8902638A priority Critical patent/SE509359C2/sv

1989-08-01 Publication of SE8902638D0 publication Critical patent/SE8902638D0/xx

1990-07-31 Priority to AT90911434T priority patent/ATE107514T1/de

1990-07-31 Priority to EP90911434A priority patent/EP0486525B1/fr

1990-07-31 Priority to PCT/SE1990/000509 priority patent/WO1991001743A1/fr

1990-07-31 Priority to DE69010206T priority patent/DE69010206T2/de

1990-07-31 Priority to JP51095890A priority patent/JP3477196B2/ja

1990-07-31 Priority to AU61439/90A priority patent/AU652124B2/en

1990-07-31 Priority to CA002064689A priority patent/CA2064689C/fr

1991-02-02 Publication of SE8902638L publication Critical patent/SE8902638L/

1993-12-08 Priority to US08/162,906 priority patent/US6267964B1/en

1999-01-18 Publication of SE509359C2 publication Critical patent/SE509359C2/sv

Links

108090000623 proteins and genes Proteins 0.000 title claims abstract description 75
102000004169 proteins and genes Human genes 0.000 title claims abstract description 69
239000003814 drug Substances 0.000 title claims abstract description 12
239000000863 peptide conjugate Substances 0.000 title claims abstract description 5
229940079593 drug Drugs 0.000 title description 3
238000002360 preparation method Methods 0.000 title description 2
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 31
230000027455 binding Effects 0.000 claims abstract description 26
229920001184 polypeptide Polymers 0.000 claims abstract description 22
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 22
238000001727 in vivo Methods 0.000 claims abstract description 15
239000012634 fragment Substances 0.000 claims abstract description 13
238000004519 manufacturing process Methods 0.000 claims abstract description 6
108010071390 Serum Albumin Proteins 0.000 claims description 9
102000007562 Serum Albumin Human genes 0.000 claims description 9
108010088160 Staphylococcal Protein A Proteins 0.000 claims description 5
108700011201 Streptococcus IgG Fc-binding Proteins 0.000 claims description 5
108060003951 Immunoglobulin Proteins 0.000 claims description 2
102000018358 immunoglobulin Human genes 0.000 claims description 2
239000000725 suspension Substances 0.000 claims description 2
229940102223 injectable solution Drugs 0.000 claims 1
229940102213 injectable suspension Drugs 0.000 claims 1
238000000034 method Methods 0.000 abstract description 15
102000004506 Blood Proteins Human genes 0.000 abstract description 6
108010017384 Blood Proteins Proteins 0.000 abstract description 6
230000001225 therapeutic effect Effects 0.000 abstract description 4
230000004071 biological effect Effects 0.000 abstract description 3
230000008878 coupling Effects 0.000 abstract description 3
238000010168 coupling process Methods 0.000 abstract description 3
238000005859 coupling reaction Methods 0.000 abstract description 3
241000124008 Mammalia Species 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
239000013612 plasmid Substances 0.000 description 13
239000013598 vector Substances 0.000 description 12
108091028043 Nucleic acid sequence Proteins 0.000 description 11
102000037865 fusion proteins Human genes 0.000 description 11
108020001507 fusion proteins Proteins 0.000 description 11
210000004027 cell Anatomy 0.000 description 9
239000000047 product Substances 0.000 description 9
230000004927 fusion Effects 0.000 description 8
241000282693 Cercopithecidae Species 0.000 description 7
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
108020004511 Recombinant DNA Proteins 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
102000023732 binding proteins Human genes 0.000 description 6
108091008324 binding proteins Proteins 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002372 labelling Methods 0.000 description 6
229920002521 macromolecule Polymers 0.000 description 6
230000035939 shock Effects 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 5
239000007983 Tris buffer Substances 0.000 description 5
239000002609 medium Substances 0.000 description 5
230000003204 osmotic effect Effects 0.000 description 5
108091034117 Oligonucleotide Proteins 0.000 description 4
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000009826 distribution Methods 0.000 description 4
238000003752 polymerase chain reaction Methods 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
108091008146 restriction endonucleases Proteins 0.000 description 4
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000001974 tryptic soy broth Substances 0.000 description 4
108010050327 trypticase-soy broth Proteins 0.000 description 4
102000009027 Albumins Human genes 0.000 description 3
108010088751 Albumins Proteins 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
101710197567 Protein LIFEGUARD 4 Proteins 0.000 description 3
102100024094 Protein lifeguard 4 Human genes 0.000 description 3
101710120037 Toxin CcdB Proteins 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
238000010367 cloning Methods 0.000 description 3
230000007423 decrease Effects 0.000 description 3
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
230000028993 immune response Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
230000009466 transformation Effects 0.000 description 3
229960005486 vaccine Drugs 0.000 description 3
VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 2
101710151325 B2 protein Proteins 0.000 description 2
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
108010042407 Endonucleases Proteins 0.000 description 2
102000004533 Endonucleases Human genes 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
101100005713 Homo sapiens CD4 gene Proteins 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
229910052921 ammonium sulfate Inorganic materials 0.000 description 2
235000011130 ammonium sulphate Nutrition 0.000 description 2
239000001166 ammonium sulphate Substances 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000000562 conjugate Substances 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
230000008105 immune reaction Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000002955 isolation Methods 0.000 description 2
239000012160 loading buffer Substances 0.000 description 2
239000006166 lysate Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
239000008188 pellet Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
108010043277 recombinant soluble CD4 Proteins 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
229960000187 tissue plasminogen activator Drugs 0.000 description 2
230000001131 transforming effect Effects 0.000 description 2
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108010076804 DNA Restriction Enzymes Proteins 0.000 description 1
102000009024 Epidermal Growth Factor Human genes 0.000 description 1
241000588722 Escherichia Species 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
241000700605 Viruses Species 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000012258 culturing Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
108010094102 enzymobeads Proteins 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
239000003446 ligand Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
244000052769 pathogen Species 0.000 description 1
210000001322 periplasm Anatomy 0.000 description 1
KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
GKBMIFPNPOSTHB-BJBKLNMKSA-N recombinant soluble cd4 Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O GKBMIFPNPOSTHB-BJBKLNMKSA-N 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
238000009210 therapy by ultrasound Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
230000007306 turnover Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Biophysics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Toxicology (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Virology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)

SE8902638A 1989-08-01 1989-08-01 Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel SE509359C2 (sv)

Priority Applications (9)

Application Number	Priority Date	Filing Date	Title
SE8902638A SE509359C2 (sv)	1989-08-01	1989-08-01	Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
CA002064689A CA2064689C (fr)	1989-08-01	1990-07-31	Conjugues de proteines ou de peptides stabilises
DE69010206T DE69010206T2 (de)	1989-08-01	1990-07-31	Stabilisierte protein- oder peptidkonjugate.
EP90911434A EP0486525B1 (fr)	1989-08-01	1990-07-31	Conjugues de proteines ou de peptides stabilises
PCT/SE1990/000509 WO1991001743A1 (fr)	1989-08-01	1990-07-31	Conjugues de proteines ou de peptides stabilises
AT90911434T ATE107514T1 (de)	1989-08-01	1990-07-31	Stabilisierte protein- oder peptidkonjugate.
JP51095890A JP3477196B2 (ja)	1989-08-01	1990-07-31	安定化されたタンパク質またはペプチド接合体
AU61439/90A AU652124B2 (en)	1989-08-01	1990-07-31	Stabilized protein or peptide conjugates
US08/162,906 US6267964B1 (en)	1989-08-01	1993-12-08	Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE8902638A SE509359C2 (sv)	1989-08-01	1989-08-01	Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel

Publications (3)

Publication Number	Publication Date
SE8902638D0 SE8902638D0 (sv)	1989-08-01
SE8902638L SE8902638L (sv)	1991-02-02
SE509359C2 true SE509359C2 (sv)	1999-01-18

Family

ID=20376608

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE8902638A SE509359C2 (sv)	1989-08-01	1989-08-01	Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel

Country Status (8)

Country	Link
EP (1)	EP0486525B1 (fr)
JP (1)	JP3477196B2 (fr)
AT (1)	ATE107514T1 (fr)
AU (1)	AU652124B2 (fr)
CA (1)	CA2064689C (fr)
DE (1)	DE69010206T2 (fr)
SE (1)	SE509359C2 (fr)
WO (1)	WO1991001743A1 (fr)

Families Citing this family (208)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5612034A (en) *	1990-10-03	1997-03-18	Redcell, Inc.	Super-globuling for in vivo extended lifetimes
AU1843295A (en) *	1994-02-23	1995-09-11	Chiron Corporation	Method and compositions for increasing the serum half-life of pharmacologically active agents
FR2726471B1 (fr) *	1994-11-07	1997-01-31	Pf Medicament	Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
EP0851767A1 (fr) *	1995-09-21	1998-07-08	Quadrant Healthcare (UK) Limited	Vehicules et stimulateurs de transcytose pour l'administration de medicaments
US20020193571A1 (en) *	1996-01-08	2002-12-19	Paul J. Carter	Wsx receptor agonist antibodies
US20050019325A1 (en)	1996-01-08	2005-01-27	Carter Paul J.	WSX receptor agonist antibodies
US7074397B1 (en)	1996-01-08	2006-07-11	Genentech, Inc.	Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en)	1996-01-08	2003-04-01	Genentech, Inc.	Leptin receptor having a WSX motif
ATE473759T1 (de)	1998-05-22	2010-07-15	Univ Leland Stanford Junior	Bifunktionelle moleküle sowie darauf basierende therapien.
US20030190740A1 (en)	1998-10-13	2003-10-09	The University Of Georgia Research Foundation, Inc	Stabilized bioactive peptides and methods of identification, synthesis, and use
DE69926009D1 (de)	1998-10-13	2005-08-04	Univ Georgia Res Found	Stabilisierte bioaktive peptide und methoden zu ihrer identifikation, synthese und verwendung
US7220552B1 (en)	1999-11-19	2007-05-22	The Board Of Trustees Of The Leland Stanford Junior University	Bifunctional molecules and their use in the disruption of protein-protein interactions
EP1229793A4 (fr) *	1999-11-19	2003-01-22	Univ Leland Stanford Junior	Molecules bifonctionnelles ayant des proprietes pharmacocinetiques modulees, et therapies a base de ces molecules
AU2044001A (en)	1999-11-19	2001-05-30	Board Of Trustees Of The Leland Stanford Junior University	Targeted bifunctional molecules and therapies based thereon
US6887842B1 (en)	1999-11-19	2005-05-03	The Board Of Trustees Of The Leland Stanford Junior University	Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
EP1757701A1 (fr) *	1999-12-24	2007-02-28	Genentech, Inc.	Procédés et compositions pour la prolongation de la demi-vie d'élimination des composés bioactifs
WO2001045746A2 (fr) *	1999-12-24	2001-06-28	Genentech, Inc.	Methodes et compositions permettant de prolonger les demi-vies d'elimination de composes bioactifs
CA2440582A1 (fr)	2001-03-09	2002-10-03	Dyax Corp.	Groupes de liaison d'albumine serique
US20030157561A1 (en) *	2001-11-19	2003-08-21	Kolkman Joost A.	Combinatorial libraries of monomer domains
EP2075256A2 (fr)	2002-01-14	2009-07-01	William Herman	Ligands ciblés
JP2005521733A (ja)	2002-03-26	2005-07-21	ダイアックス、コープ	フィブリノーゲン結合部分
EP1837031B1 (fr)	2002-06-07	2009-10-14	Waratah Pharmaceuticals, Inc.	Methodes et compositions pour le traitement du diabete
DK1517921T3 (da) *	2002-06-28	2006-10-09	Domantis Ltd	Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US9321832B2 (en)	2002-06-28	2016-04-26	Domantis Limited	Ligand
EP3299393A1 (fr)	2002-11-08	2018-03-28	Ablynx N.V.	Anticorps à domaine unique dirigés contre le facteur alpha de la nécrose tumorale et leurs utilisations
US9320792B2 (en)	2002-11-08	2016-04-26	Ablynx N.V.	Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20060034845A1 (en)	2002-11-08	2006-02-16	Karen Silence	Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
DE05733048T1 (de) *	2004-04-06	2007-05-10	Affibody Ab	Serumalbuminbindende peptidkonjugate zur arzneimittelherstellung
KR20120133403A (ko) *	2004-06-01	2012-12-10	도만티스 리미티드	증강된 혈청 반감기를 가지는 이특이성 융합 항체
US7563443B2 (en)	2004-09-17	2009-07-21	Domantis Limited	Monovalent anti-CD40L antibody polypeptides and compositions thereof
BRPI0516577A (pt) *	2004-10-05	2008-09-16	Genentech Inc	agentes terapêuticos com toxicidade diminuìda
GB0426146D0 (en)	2004-11-29	2004-12-29	Bioxell Spa	Therapeutic peptides and method
BRPI0518762A2 (pt) *	2004-12-02	2008-12-09	Domantis Ltd	fusço de droga, conjugado de droga, Ácido nucleico recombinante ou isolado, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir a fusço de droga, composiÇço farmacÊutica, mÉtodo para tratamento de um indivÍduo tendo uma doenÇa inflamatària, uso de um conjugado de droga ou fusço de droga, e, composiÇço de droga
CA2589800A1 (fr) *	2004-12-02	2006-06-08	Domantis Limited	Anticorps a domaine bispecifiques ciblant l'albumine serique et le glp 1ou le pyy
KR20070086896A (ko) *	2004-12-02	2007-08-27	도만티스 리미티드	항ｉｌ1ｒ1 단일 도메인 항체 및 치료적 용도
CN103254309B (zh)	2005-05-18	2017-09-26	埃博灵克斯股份有限公司	针对肿瘤坏死因子α的改进的纳米体TM
EP1940880A2 (fr) *	2005-10-14	2008-07-09	Novo Nordisk A/S	Traitement du diabete a l'aide d'inhibiteurs de l'il-1
ATE536369T1 (de) *	2006-10-11	2011-12-15	Ablynx Nv	Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung
GB0621513D0 (en)	2006-10-30	2006-12-06	Domantis Ltd	Novel polypeptides and uses thereof
EP2115004A2 (fr)	2006-12-19	2009-11-11	Ablynx N.V.	Sequences d'acides amines dirigees contre les gpcr et polypeptides les contenant pour le traitement de maladies et de troubles lies au gpcr
US9512236B2 (en)	2006-12-19	2016-12-06	Ablynx N.V.	Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP2514767A1 (fr)	2006-12-19	2012-10-24	Ablynx N.V.	Séquences d'acides aminés dirigées contre une métalloprotéinase de la famille ADAM et polypeptides les comprenant pour le traitement de maladies et troubles liés à ADAM
DE08786222T1 (de)	2007-07-31	2010-11-25	Affibody Ab	Neue albuminbindende zusammensetzungen, verfahren und anwendungen
ES2667729T3 (es)	2007-09-26	2018-05-14	Ucb Biopharma Sprl	Fusiones de anticuerpos con doble especificidad
TWI489993B (zh)	2007-10-12	2015-07-01	Novartis Ag	骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
CN101970490A (zh)	2007-11-27	2011-02-09	埃博灵克斯股份有限公司	针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
ES2373832T3 (es)	2007-12-19	2012-02-09	Affibody Ab	Polipéptido derivado de proteína a y capaz de unirse a pdgf.
US9187535B2 (en)	2007-12-19	2015-11-17	Affibody Ab	Polypeptide derived from protein A and able to bind PDGF
EP2077272A1 (fr)	2007-12-21	2009-07-08	Affibody AB	Librairies de polypeptides avec une structure d'échafaudage prédéterminée
EP2072525A1 (fr)	2007-12-21	2009-06-24	Affibody AB	Nouveaux polypeptides présentant une affinité de liaison pour HER2
WO2009124931A2 (fr)	2008-04-07	2009-10-15	Ablynx Nv	Séquences d'acides aminés dirigées contre les voies notch et leurs utilisations
US9212226B2 (en)	2008-05-16	2015-12-15	Ablynx N.V.	Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
DK2285408T3 (en)	2008-06-05	2019-02-04	Ablynx Nv	AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES
WO2010035012A1 (fr)	2008-09-26	2010-04-01	Ucb Pharma S.A.	Produits biologiques
EP2346900A1 (fr)	2008-10-29	2011-07-27	Wyeth LLC	Procédés de purification de molécules de liaison d'antigène monodomaines
EP3011953A1 (fr)	2008-10-29	2016-04-27	Ablynx N.V.	Formulations stabilisées de molécules de liaison d'antigène monodomaines
CA2747644C (fr)	2008-12-19	2023-01-24	Ablynx N.V.	Procede de generation de sequences d'immunoglobulines
US20120165650A1 (en)	2010-12-22	2012-06-28	General Electric Company	Her2 binders
EP2417163B1 (fr)	2009-04-10	2019-02-27	Ablynx N.V.	Séquences d'acides aminés améliorées dirigées contre il-6r et polypeptides comprenant celles-ci pour le traitement de maladies et de troubles associés à il-6r
BRPI1016055A2 (pt)	2009-04-27	2016-05-10	Novartis Ag	composição e métodos de uso para anticorpos terapêuticos específicos para a subunidade beta i do receptor de il-12
NO2424895T3 (fr)	2009-04-27	2018-02-03
MX340541B (es)	2009-06-05	2016-07-13	Alblynx Nv	Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio.
WO2011029823A1 (fr)	2009-09-09	2011-03-17	Novartis Ag	Anticorps monoclonal réactif avec cd63 lors de son expression à la surface de mastocytes dégranulés
GB201005063D0 (en)	2010-03-25	2010-05-12	Ucb Pharma Sa	Biological products
JP5960598B2 (ja)	2009-11-04	2016-08-02	アフィボディ・アーベー	Ｈｅｒ３結合ポリペプチド
US9644022B2 (en)	2009-11-30	2017-05-09	Ablynx N.V.	Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
US8962807B2 (en)	2009-12-14	2015-02-24	Ablynx N.V.	Single variable domain antibodies against OX40L, constructs and therapeutic use
AU2010334974A1 (en)	2009-12-22	2012-07-12	Novartis Ag	Tetravalent CD47-antibody constant region fusion protein for use in therapy
WO2011083140A1 (fr)	2010-01-08	2011-07-14	Ablynx Nv	Domaines variables simples d'immunoglobuline dirigés contre le cxcr4 doués d'une meilleure activité thérapeutique et produits de recombinaison les comprenant
US9120855B2 (en)	2010-02-10	2015-09-01	Novartis Ag	Biologic compounds directed against death receptor 5
WO2011117423A1 (fr)	2010-03-26	2011-09-29	Ablynx N.V.	Domaines variables uniques de l'immunoglobuline dirigés contre cxcr7
AU2011245980A1 (en) *	2010-04-30	2012-11-08	Sanwa Kagaku Kenkyusho Co., Ltd.	Peptide for improving in vivo stability of physiologically active substance or the like and physiologically active substance with improved in vivo stability
SG185354A1 (en)	2010-05-20	2012-12-28	Ablynx Nv	Biological materials related to her3
CN110437321A (zh)	2010-07-09	2019-11-12	阿菲博迪公司	多肽
EP3028720A1 (fr)	2010-09-28	2016-06-08	Amylin Pharmaceuticals, LLC	Polypeptides modifiés à durée d'action accrue
WO2012042026A1 (fr)	2010-09-30	2012-04-05	Ablynx Nv	Matières biologiques associées à c-met
JP2013543384A (ja)	2010-10-05	2013-12-05	ノバルティスアーゲー	抗−ｉｌ１２ｒベータ１抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
KR101650995B1 (ko)	2010-11-08	2016-08-25	노파르티스 아게	Ｃｘｃｒ２ 결합 폴리펩티드
US9221892B2 (en)	2010-11-26	2015-12-29	Molecular Partners Ag	Capping modules for designed ankyrin repeat proteins
CA2827170A1 (fr)	2011-02-11	2012-08-16	David M. Hilbert	Complexes plurispecifiques monovalents et multivalents et leurs utilisations
US20150158948A9 (en)	2011-03-28	2015-06-11	Francis Descamps	Bispecific anti-cxcr7 immunoglobulin single variable domains
UA117218C2 (uk)	2011-05-05	2018-07-10	Мерк Патент Гмбх	Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
PL2707391T3 (pl)	2011-05-13	2018-04-30	Gamamabs Pharma	Przeciwciała przeciwko her3
RU2661677C2 (ru)	2011-05-27	2018-07-18	Аблинкс Нв	Ингибирование резорбции кости с помощью связывающих rank-l пептидов
WO2012172521A1 (fr)	2011-06-16	2012-12-20	Novartis Ag	Protéines solubles destinées à être utilisées comme agents thérapeutiques
AU2012273955A1 (en)	2011-06-22	2014-01-09	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Anti-Axl antibodies and uses thereof
WO2012175691A1 (fr)	2011-06-22	2012-12-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anticorps anti-axl et utilisations associées
JP2014525736A (ja)	2011-06-23	2014-10-02	アブリンクスエン．ヴェー．	ＩｇＥに対する免疫グロブリン単一可変ドメイン
PL2726099T3 (pl)	2011-07-01	2018-12-31	Novartis Ag	Sposób leczenia zaburzeń metabolicznych
CA2849409A1 (fr)	2011-09-23	2013-03-28	Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa	Agents du facteur de necrose tumorale alpha et utilisations de ceux-ci
WO2013041722A1 (fr)	2011-09-23	2013-03-28	Ablynx Nv	Inhibition prolongée d'une signalisation à médiation par l'interleukine-6
CA2849705A1 (fr)	2011-09-23	2013-03-28	Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa	Domaines de liaison a l'albumine modifies et utilisations de ceux-ci pour ameliorer la pharmacocinetique
EP2747783B1 (fr)	2011-09-30	2017-06-14	Ablynx N.V.	Substances biologiques liées à c-met
SG11201401649VA (en)	2011-11-11	2014-07-30	Ucb Pharma Sa	Albumin binding antibodies and binding fragments thereof
WO2013126006A1 (fr)	2012-02-20	2013-08-29	Swedish Orphan Biovitrum Ab (Publ)	Polypeptides se fixant au composant c5 du complément humain
JP2020033372A (ja) *	2012-03-28	2020-03-05	アフィボディ・アーベー	経口投与
JP2015512902A (ja) *	2012-03-28	2015-04-30	アフィボディ・アーベー	経口投与
US9328174B2 (en)	2012-05-09	2016-05-03	Novartis Ag	Chemokine receptor binding polypeptides
CN108524919A (zh)	2012-05-17	2018-09-14	延伸生物科学股份有限公司	用于改进的药物递送的载体
JP6590695B2 (ja)	2012-09-25	2019-10-16	アフィボディ・アーベー	アルブミン結合ポリペプチド
KR102191655B1 (ko)	2012-10-05	2020-12-16	애피바디 에이비	Her3 결합 폴리펩티드
KR102151289B1 (ko)	2012-10-25	2020-09-02	애피바디 에이비	Abd 결합 폴리펩티드
EP2912051B1 (fr)	2012-10-25	2018-04-18	Affibody AB	Procédé de séparation de protéines contenant un domaine de liaison à l'albumine
WO2014076179A1 (fr)	2012-11-14	2014-05-22	Affibody Ab	Nouveau polypeptide
EP2752426A1 (fr)	2013-01-03	2014-07-09	Covagen AG	Composés de liaison d'albumine de sérum humain et leurs protéines de fusion
AP2015008584A0 (en)	2013-02-08	2015-07-31	Novartis Ag	Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
WO2014165093A2 (fr)	2013-03-13	2014-10-09	Bristol-Myers Squibb Company	Domaines d'échafaudage à base de fibronectine liés à une sérum albumine ou fragment se liant à celle-ci
EP3013370A1 (fr)	2013-06-24	2016-05-04	Riogin Corporation	Constructions à double liaison
TW201536318A (zh)	2013-08-14	2015-10-01	Novartis Ag	治療偶發性包涵體肌炎之方法
PT3038633T (pt)	2013-08-28	2021-01-14	Ipc Res Llc	Polipéptidos estáveis que se ligam ao complemento humano c5
KR102497083B1 (ko)	2013-08-28	2023-02-07	애피바디 에이비	돌연변이된 스캐폴드를 갖는 결합 폴리펩티드
RU2704228C2 (ru)	2013-11-07	2019-10-24	Инсерм (Институт Насьональ Де Ла Сант Эт Де Ла Решерш Медикаль)	Неконкурентные в отношении нейрегулина аллостерические антитела против человеческого her3 и их применения
WO2015091957A1 (fr)	2013-12-20	2015-06-25	Affibody Ab	Polypeptide modifié liant l'albumine
TW201622746A (zh)	2014-04-24	2016-07-01	諾華公司	改善或加速髖部骨折術後身體復原之方法
NL2013661B1 (en)	2014-10-21	2016-10-05	Ablynx Nv	KV1.3 Binding immunoglobulins.
US20170291939A1 (en)	2014-06-25	2017-10-12	Novartis Ag	Antibodies specific for il-17a fused to hyaluronan binding peptide tags
WO2016065042A1 (fr)	2014-10-22	2016-04-28	Extend Biosciences, Inc.	Conjugués de vitamine d thérapeutiques
US9789197B2 (en)	2014-10-22	2017-10-17	Extend Biosciences, Inc.	RNAi vitamin D conjugates
WO2016065052A1 (fr)	2014-10-22	2016-04-28	Extend Biosciences, Inc.	Conjugués insuline vitamine d
CA2969307A1 (fr) *	2014-12-04	2016-06-09	Novartis Ag	Procedes et compositions employant des polypeptides variants de klotho
WO2016100803A2 (fr)	2014-12-19	2016-06-23	Alexion Pharmaceuticals, Inc.	Méthodes de traitement d'une calcification tissulaire
RU2769470C2 (ru)	2015-04-02	2022-04-01	Молекьюлар Партнерс Аг	Рекомбинантные связывающие белки и их применение
ES3029413T3 (en)	2015-04-02	2025-06-24	Ablynx Nv	Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity
SI3294319T1 (sl)	2015-05-13	2024-09-30	Ablynx Nv	Polipeptidi, ki rekrutirajo celice T na osnovi reaktivnosti CD3
EP3611192B1 (fr)	2015-05-13	2025-03-05	Ablynx N.V.	Polypeptides de recrutement de lymphocytes t basés sur la réactivité tcr alpha/bêta
EP3298044B1 (fr)	2015-05-22	2021-08-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Fragments d'anticorps monoclonaux humains pour inhiber à la fois l'activité cath-d catalytique et sa liaison au récepteur lrp1
WO2016193380A1 (fr)	2015-06-02	2016-12-08	Novo Nordisk A/S	Insulines à extensions recombinées polaires
HK1255383A1 (zh)	2015-07-31	2019-08-16	The Research Institute At Nationwide Children's Hospital	去除生物膜的肽及抗體
MA43348A (fr)	2015-10-01	2018-08-08	Novo Nordisk As	Conjugués de protéines
WO2017066719A2 (fr)	2015-10-14	2017-04-20	Research Institute At Nationwide Children's Hospital	Agents spécifiques interférant avec hu
RS64053B1 (sr)	2015-10-30	2023-04-28	Univ California	Polipeptidi koji reaguju na transformišući faktor rasta – beta i postupci za njihovu upotrebu
CA3006398A1 (fr)	2015-11-27	2017-06-01	Ablynx Nv	Polypeptides inhibant le ligand cd40l
EP3471747A1 (fr)	2016-06-16	2019-04-24	Alexion Pharmaceuticals, Inc.	Méthodes de traitement d'une prolifération myo-intimale
WO2018007442A1 (fr)	2016-07-06	2018-01-11	Ablynx N.V.	Traitement de maladies associées à l'il-6r
ES3041722T3 (en)	2016-07-29	2025-11-14	Inst Nat Sante Rech Med	Antibodies targeting tumor associated macrophages and uses thereof
WO2018029182A1 (fr)	2016-08-08	2018-02-15	Ablynx N.V.	Anticorps à domaine variable unique d'il-6r pour le traitement de maladies liées à l'il-6r
JP2019530440A (ja)	2016-09-02	2019-10-24	ザリージェンツオブザユニバーシティオブカリフォルニア	インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物
EP3512880A1 (fr)	2016-09-15	2019-07-24	Ablynx NV	Domaines variables uniques d'immunoglobuline dirigés contre le facteur inhibiteur de la migration des macrophages
CN109790206A (zh)	2016-09-22	2019-05-21	分子组合公司	重组结合蛋白及其用途
AU2017361846B2 (en)	2016-11-16	2024-08-22	Ablynx Nv	T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
EP3565589A1 (fr)	2017-01-04	2019-11-13	Research Institute at Nationwide Children's Hospital	Anticorps et vaccins dnabii présentant une activité améliorée
WO2018129092A1 (fr)	2017-01-04	2018-07-12	Research Institute At Nationwide Children's Hospital	Fragments d'anticorps pour le traitement de troubles liés au biofilm
CN110392697A (zh)	2017-03-02	2019-10-29	国家医疗保健研究所	对nectin-4具有特异性的抗体及其用途
EP3595445B1 (fr)	2017-03-15	2024-09-04	The Research Institute at Nationwide Children's Hospital	Composition et procédés de rupture de biofilms bactériens sans inflammation associée
CA3054837A1 (fr)	2017-03-24	2018-09-27	Novartis Ag	Procede pour la prevention et le traitement de maladies cardiaques
WO2018185131A2 (fr)	2017-04-05	2018-10-11	Novo Nordisk A/S	Conjugués insuline-fc à extension oligomère
CN110997716B (zh)	2017-06-02	2024-03-15	埃博灵克斯股份有限公司	结合聚集蛋白聚糖的免疫球蛋白
KR102778120B1 (ko)	2017-06-02	2025-03-06	메르크 파텐트 게엠베하	Mmp13 결합성 면역글로불린
LT3630847T (lt)	2017-06-02	2024-12-10	Merck Patent Gmbh	Adamts surišantys imunoglobulinai
IL270951B2 (en)	2017-06-02	2025-05-01	Merck Patent Gmbh	ADAMTS5, MMP13 and aggrecan-binding polypeptides
JP2020525421A (ja)	2017-06-28	2020-08-27	ノバルティスアーゲー	尿失禁を予防及び治療するための方法
BR112019028269A2 (pt)	2017-07-11	2020-07-14	Alexion Pharmaceuticals, Inc.	polipeptídeos que se ligam ao componente c5 do complemento ou à albumina sérica e suas proteínas de fusão
US12134790B2 (en)	2017-09-27	2024-11-05	Inozyme Pharma, Inc.	Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
AU2018348429B2 (en)	2017-10-10	2025-08-28	Numab Therapeutics AG	Multispecific antibody
EP3470426A1 (fr)	2017-10-10	2019-04-17	Numab Therapeutics AG	Anticorps multi-spécifique
EP3552631A1 (fr)	2018-04-10	2019-10-16	Inatherys	Conjugués d'anticorps-médicament et leurs utilisations pour le traitement du cancer
CN113840832A (zh)	2018-05-14	2021-12-24	狼人治疗公司	可活化白介素-2多肽及其使用方法
MX2020012252A (es)	2018-05-14	2021-04-28	Werewolf Therapeutics Inc	Polipeptidos de interleucina 12 activables y metodos de uso de los mismos.
KR20210022004A (ko)	2018-06-18	2021-03-02	안위타 바이오사이언시스, 인코포레이티드	항-메소텔린 작제물 및 이의 용도
US11987631B2 (en)	2018-08-01	2024-05-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti-BTN3A antibodies and their use in treating cancer or infectious disorders
WO2020053122A1 (fr)	2018-09-10	2020-03-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Combinaison d'anticorps her2/neu avec de l'hème pour le traitement du cancer
KR20250154552A (ko)	2018-09-27	2025-10-28	실리오 디벨럽먼트, 인크.	마스킹된 사이토카인 폴리펩타이드
AU2019355194A1 (en)	2018-10-05	2021-04-22	Research Institute At Nationwide Children's Hospital	Compositions and methods for enzymatic disruption of bacterial biofilms
EP3947446A1 (fr)	2019-03-25	2022-02-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Traitement de troubles de tauopathie par ciblage de nouvelles espèces tau
EP3969035A4 (fr)	2019-05-14	2023-06-21	Werewolf Therapeutics, Inc.	Groupes caractéristiques de séparation, procédés et utilisation associés
MX2021014649A (es)	2019-06-04	2022-01-06	Molecular Partners Ag	Dominio de repetición de anquirina diseñado con estabilidad mejorada.
EP3983437A1 (fr)	2019-06-12	2022-04-20	Novartis AG	Anticorps du récepteur 1 du peptide natriurétique et procédés d'utilisation
BR112021026890A2 (pt)	2019-07-08	2022-03-15	Res Inst Nationwide Childrens Hospital	Composições de anticorpo para interromper biofilmes
EP3785726A1 (fr)	2019-09-02	2021-03-03	Biotest AG	Protéine de facteur viii à demi-vie prolongée
JP2022546525A (ja)	2019-09-02	2022-11-04	ビオテスト・アクチエンゲゼルシャフト	延長された半減期を有する第ｖｉｉｉ因子タンパク質
WO2021058729A1 (fr)	2019-09-27	2021-04-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anticorps dirigés contre le récepteur de type i d'une substance inhibitrice anti-mullérienne et leurs utilisations
WO2021058763A1 (fr)	2019-09-27	2021-04-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anticorps de de substance inhibitrice müllérienne et leurs utilisations
WO2021076930A1 (fr)	2019-10-18	2021-04-22	The Regents Of The University Of California	Activateurs plxdc et leur utilisation dans le traitement de troubles des vaisseaux sanguins
EP3816185A1 (fr)	2019-11-04	2021-05-05	Numab Therapeutics AG	Anticorps multi-spécifique contra pd-l1 et antigène associé à une tumeur
WO2021097376A1 (fr)	2019-11-14	2021-05-20	Werewolf Therapeutics, Inc.	Polypeptides de cytokine activables et leurs méthodes d'utilisation
US20230040928A1 (en)	2019-12-09	2023-02-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies having specificity to her4 and uses thereof
GB201919061D0 (en)	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Multi-specific antibody
WO2021140209A1 (fr)	2020-01-10	2021-07-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Protéines rspo1 et leur utilisation
WO2021165226A1 (fr)	2020-02-17	2021-08-26	Biotest Ag	Administration sous-cutanée de facteur viii
CA3180683A1 (fr)	2020-05-12	2021-11-18	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Nouveau procede de traitement de lymphomes cutanes a lymphocytes t et de lymphomes derives de tfh
EP3915580A1 (fr)	2020-05-29	2021-12-01	Numab Therapeutics AG	Anticorps multi-spécifique
US20230265211A1 (en)	2020-06-29	2023-08-24	Inserm (Institut National De La Santé Et De Ls Recherche Médicale)	Anti-protein s single-domain antibodies and polypeptides comprising thereof
EP3988568A1 (fr)	2020-10-21	2022-04-27	Numab Therapeutics AG	Traitement combiné
WO2022098743A1 (fr)	2020-11-03	2022-05-12	Indi Molecular, Inc.	Compositions, imagerie et procédés thérapeutiques ciblant le récepteur 1 de folate (folr1)
WO2022098745A1 (fr)	2020-11-03	2022-05-12	Indi Molecular, Inc.	Compositions, systèmes d'administration et méthodes utiles dans la thérapie antitumorale
EP4251187A4 (fr)	2020-11-25	2025-09-10	Xilio Dev Inc	Lieurs clivables spécifiques aux tumeurs
IL303295A (en)	2020-12-07	2023-07-01	UCB Biopharma SRL	Multi-specific antibodies and antibody combinations
WO2022130182A1 (fr)	2020-12-14	2022-06-23	Novartis Ag	Agents d'inversion de liaison pour anticorps anti-récepteur 1 du peptide natriurétique (npr1) et leurs utilisations
PE20250740A1 (es)	2021-02-02	2025-03-13	Numab Therapeutics AG	Anticuerpos multiespecificos con especificidad para ror1 y cd3
WO2022171892A1 (fr)	2021-02-15	2022-08-18	Affibody Ab	Nouveau polypeptide de liaison à her2
CA3209052A1 (fr)	2021-02-19	2022-08-25	Rafael Cristian CASELLAS	Anticorps a domaine unique qui neutralisent le sars-cov-2
WO2023052541A1 (fr)	2021-09-30	2023-04-06	Imcheck Therapeutics	Combinaison d'un anticorps d'activation anti-btn3a et d'un agoniste il-2 en vue d'une utilisation en thérapie
EP4183800A1 (fr)	2021-11-19	2023-05-24	Medizinische Hochschule Hannover	Nouveaux anticorps neutralisants du sars-cov-2
JP2025510997A (ja)	2022-03-30	2025-04-15	ノバルティスアーゲー	抗ナトリウム利尿ペプチド受容体１（ｎｐｒ１）抗体を使用して障害を治療する方法
WO2024038095A1 (fr)	2022-08-16	2024-02-22	Iome Bio	Nouveaux anticorps anti-rgmb
WO2024052503A1 (fr)	2022-09-08	2024-03-14	Institut National de la Santé et de la Recherche Médicale	Anticorps présentant une spécificité pour ltbp2 et leurs utilisations
CN120225559A (zh)	2022-09-12	2025-06-27	国家健康与医学研究院	新型抗itgb8抗体及其用途
JP2025534350A (ja)	2022-09-30	2025-10-15	エクステンドバイオサイエンシズインコーポレーテッド	長時間作用型副甲状腺ホルモン
KR20250080883A (ko)	2022-10-04	2025-06-05	임체크 테라퓨틱스	암 치료에 사용하기 위한 BTN3A 활성화 항체, Bcl-2 억제제 및 저메틸화제의 조합
WO2024083843A1 (fr)	2022-10-18	2024-04-25	Confo Therapeutics N.V.	Séquences d'acides aminés dirigées contre le récepteur de la mélanocortine 4 et polypeptides les comprenant pour le traitement de maladies et de troubles liés à mc4r
AU2024225483A1 (en)	2023-02-23	2025-08-28	Imcheck Therapeutics	Combination of btn3a activating antibody and immune checkpoint inhibitors
AU2024245676A1 (en)	2023-03-30	2025-10-09	272BIO Limited	Gnrh-binding polypeptides and uses thereof
AU2024273407A1 (en)	2023-05-17	2025-12-04	Centre National De La Recherche Scientifique	Anti-cathepsin-d antibodies
EP4477236A1 (fr)	2023-06-14	2024-12-18	Inatherys	Polythérapie pour le traitement d'une tumeur à l'aide d'un adc comprenant des anticorps anti-cd71 et des mimétiques bh3
WO2025012417A1 (fr)	2023-07-13	2025-01-16	Institut National de la Santé et de la Recherche Médicale	Anticorps à fragments longs anti-neurotensine et anti-neuromédine n et leurs utilisations
WO2025158010A1 (fr)	2024-01-25	2025-07-31	Affibody Ab	Polypeptide de liaison à her2
WO2025224297A1 (fr)	2024-04-26	2025-10-30	Institut National de la Santé et de la Recherche Médicale	Anticorps ayant une spécificité vis-à-vis de tgfbi et leurs utilisations
WO2025242732A1 (fr)	2024-05-21	2025-11-27	Institut National de la Santé et de la Recherche Médicale	Anticorps pan dirigés contre la protéine de spicule du sars-cov-2 et leurs utilisations à des fins thérapeutiques

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2148299B (en) *	1983-09-01	1988-01-06	Hybritech Inc	Antibody compositions of therapeutic agents having an extended serum half-life
US4666884A (en) *	1984-04-10	1987-05-19	New England Deaconess Hospital	Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
SE8505922D0 (sv) *	1985-12-13	1985-12-13	Kabigen Ab	Construction of an igg binding protein to facilitate downstream processing using protein engineering
DE3879395T2 (de) *	1987-05-29	1993-06-24	Central Glass Co Ltd	Fusionsprotein, enthaltend lymphotoxin.
GB8728856D0 (en) *	1987-12-10	1988-01-27	Bradwell A R	Tumour-locating agents & method of locating tumours

1989
- 1989-08-01 SE SE8902638A patent/SE509359C2/sv not_active IP Right Cessation
1990
- 1990-07-31 WO PCT/SE1990/000509 patent/WO1991001743A1/fr not_active Ceased
- 1990-07-31 CA CA002064689A patent/CA2064689C/fr not_active Expired - Lifetime
- 1990-07-31 EP EP90911434A patent/EP0486525B1/fr not_active Expired - Lifetime
- 1990-07-31 JP JP51095890A patent/JP3477196B2/ja not_active Expired - Lifetime
- 1990-07-31 AT AT90911434T patent/ATE107514T1/de not_active IP Right Cessation
- 1990-07-31 AU AU61439/90A patent/AU652124B2/en not_active Expired
- 1990-07-31 DE DE69010206T patent/DE69010206T2/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
SE8902638D0 (sv)	1989-08-01
DE69010206D1 (de)	1994-07-28
JPH04507242A (ja)	1992-12-17
CA2064689C (fr)	2002-04-30
AU652124B2 (en)	1994-08-18
AU6143990A (en)	1991-03-11
EP0486525A1 (fr)	1992-05-27
WO1991001743A1 (fr)	1991-02-21
ATE107514T1 (de)	1994-07-15
CA2064689A1 (fr)	1991-02-02
EP0486525B1 (fr)	1994-06-22
SE8902638L (sv)	1991-02-02
JP3477196B2 (ja)	2003-12-10
DE69010206T2 (de)	1994-10-13

Publication	Publication Date	Title
SE509359C2 (sv)	1999-01-18	Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6267964B1 (en)	2001-07-31	Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
US11060097B2 (en)	2021-07-13	Immunotherapy methods using anti-PD-L1 antibodies in combination with EGFR1 targeted-TGF-beta immunomodulatory fusion proteins
KR100484084B1 (ko)	2005-04-20	키메라성 폴리펩타이드, 이의 제조 방법 및 용도
KR100376544B1 (ko)	2003-06-12	티(t)세포조절물질및방법
UA129980C2 (uk)	2025-10-01	Конструкція на основі антитіл для зв'язування cldn18.2 і cd3
EP0335243A2 (fr)	1989-10-04	Angiogénine mutante humaine (facteur d'angiogénèse avec une activité d'angiogénine supérieure), gènes pour celle-ci et méthode d'expression
NL8104400A (nl)	1982-04-16	Microbiele bereiding van menselijk fibroblast interferon.
JPH06505631A (ja)	1994-06-30	巨核球刺激因子
US20250179447A1 (en)	2025-06-05	Solubilized apyrases, methods and use
JPH05508847A (ja)	1993-12-09	伝達因子および使用方法
JPH0797995B2 (ja)	1995-10-25	ペプチド類の製造法
CN109776653B (zh)	2022-05-17	一种人血清白蛋白黏附肽及其应用
CN113896805B (zh)	2022-02-25	一种vegf-crm197重组融合蛋白疫苗及其制备方法和应用
JPH03501201A (ja)	1991-03-22	組み換え技術により産生した、３−デス−ヒドロキシ−シスタチンｃポリペプチドまたはその修飾物
WO1993003061A1 (fr)	1993-02-18	Multiplicateur de cellules souches hematopoietiques
Sjolander et al.	1993	Bacterial Expression Systems Based on a Protein A and Protein G Designed for the Production of Immunogens: Applications to Plasmodium falciparum Malaria Antigens
CN102260352B (zh)	2013-11-20	靶向性白细胞介素融合蛋白及其制备方法与应用
CN112552389B (zh)	2023-06-06	一种活性肽融合蛋白及其制备方法
US7223412B1 (en)	2007-05-29	Staphylococcal enterotoxin SEC-SER, expression vector and host cell, production method thereof, and manufacturing method of vaccine
JP2519561B2 (ja)	1996-07-31	酸性糖タンパク質
CN101812135B (zh)	2012-03-21	具有高效升血小板作用的融合蛋白及其制备方法
CN111808202B (zh)	2020-12-11	产气荚膜梭菌基因工程亚单位疫苗、其制备方法及应用
JPH02500640A (ja)	1990-03-08	所定のポリペプチドと糖に対して親和性のタンパク質とをコードする核酸配列を含む組換体ｄｎａにより形質転換された宿主生物中で該ポリペプチドを製造する方法。応用、特にワクチン組成物の製造への応用
CN112480262B (zh)	2022-10-28	一种融合蛋白及其制备与应用

Legal Events

Date	Code	Title	Description
2009-10-13	NUG	Patent has lapsed